Search for a trial | Research with human participants

1 results

HERTHENA-Lung02: A Phase 3, Randomized, Open-label Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced Epidermal Growth Factor Receptor-mutated (EGFRm) Non-small Cell Lung Cancer (NSCLC) After Failure of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) Therapy

Approved WMOPending

This study has been transitioned to CTIS with ID 2023-507964-38-00 check the CTIS register for the current data. To compare the efficacy of patritumab deruxtecan versus platinumbased chemotherapy, as measured by progression-free survival (PFS),…